TBB

TBB is a cell-permeable and ATP-competitive CK2 inhibitor with an IC50 of 0.15 μM for rat liver CK2.

Product Specifications

CAS Number

[17374-26-4]

Product Name Alternative

NSC 231634; Casein Kinase II Inhibitor I

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Casein Kinase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TBB.html

Concentration

10mM

Purity

98.54

Solubility

DMSO : ≥ 100 mg/mL

Smiles

BrC1=C2C(NN=N2)=C(Br)C(Br)=C1Br

Molecular Formula

C6HBr4N3

Molecular Weight

434.71

Precautions

H302, H315, H319, H335

References & Citations

[1]De Moliner E, et al. Alternative binding modes of an inhibitor to two different kinases. Eur J Biochem. 2003 Aug;270 (15) :3174-81.|[2]Orzechowska E, et al. Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability. Oncol Rep. 2012 Jan;27 (1) :281-5.|[3]Sarno S, et al. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2') . FEBS Lett. 2001 May 4;496 (1) :44-8.|[4]Ljubimov AV, et al. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci. 2004 Dec;45 (12) :4583-91.|[5]Pagano MA, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J. 2008 Nov 1;415 (3) :353-65.|[6]Chen Z, et al. CK2α promotes advanced glycation end products-induced expressions of fibronectin and intercellular adhesion molecule-1 via activating MRTF-A in glomerular mesangial cells. Biochem Pharmacol. 2017 Dec 6;148:41-51.